Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Total	Cumulative Effect, Period of Adoption, Adjustment	Preferred Stock Series A	Preferred Stock Series C	Common Stock	Additional Paid in Capital	Additional Paid in Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated other Comprehensive Income (Loss)	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020			85,581	1,817	32,025,153
Beginning balance at Dec. 31, 2020	$ 40,520,391	$ 11,672	$ 855,808	$ 856,320	$ 3,203	$ 142,910,523	$ (3,314,663)		$ (104,105,463)	$ 3,326,335
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	0
Net loss	(6,063,517)								(6,063,517)
Stock-based compensation expense	957,871					957,871
Conversion of preferred stock to common (in shares)				(10)	92
Conversion of Series C to common	0			$ (10,000)		10,000
Issuance of common stock, net (in shares)					44,200,000
Issuance of common stock, net	82,153,600				$ 4,420	82,149,180
Ending balance (in shares) at Mar. 31, 2021			85,581	1,807	76,225,245
Ending balance at Mar. 31, 2021	117,580,017		$ 855,808	$ 846,320	$ 7,623	222,712,911		$ 0	(106,842,645)
Beginning balance (in shares) at Dec. 31, 2021			85,581	1,806	76,225,254
Beginning balance at Dec. 31, 2021	92,995,003		$ 855,808	$ 845,320	$ 7,623	224,787,547		0	(133,501,295)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	9,146							9,146
Net loss	(6,929,685)								(6,929,685)
Stock-based compensation expense	556,610					556,610
Conversion of preferred stock to common (in shares)				(5)	46
Conversion of Series C to common	0			$ (5,000)		5,000
Issuance of common stock, net (in shares)					4,317
Issuance of common stock, net	5,008					5,008
Ending balance (in shares) at Mar. 31, 2022			85,581	1,801	76,229,617
Ending balance at Mar. 31, 2022	$ 86,636,082		$ 855,808	$ 840,320	$ 7,623	$ 225,354,165		$ 9,146	$ (140,430,980)